Veradermics, Incorporated (MANE) Stock: Dividends & Earnings

Company Overview:

Market Cap: $0

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $32.00 - $131.24

0.7 Year MANE Performance Metrics:

Total Return (with DRIP): 221.1% (429.48% CAGR)

Total Return (no DRIP): 221.1% (429.48% CAGR)

Share Price: 221.1% (429.48% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $32,114

Total Return $ (with DRIP): $22,114

MANE Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

MANE Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Projected Future Returns & Dividends for MANE

Based on past 0.7-year performance, here are MANE growth metrics:

Share price CAGR of +429.48%
Dividend CAGR of +0%

Using MANE CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	MANE (DRIP)	MANE - No DRIP
Current Price	$121.23	$121.23
Start Shares	82.49	82.49
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	82.49	82.49
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$121.23	$121.23
Total Dividends	$0	$0
Final Value	$10,000	$10,000

Estimated Future Value + Dividends - MANE

NOTE: Above numbers are our estimate based on MANE's Dividend and Price CAGR over past 0.7 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

Veradermics, Incorporated (MANE) had its IPO on , and is traded on NYSE stock exchange.

Veradermics, Incorporated is a late clinical-stage biopharmaceutical company focused on developing dermatology and aesthetic treatments. Its current pipeline centers on therapies for pattern hair loss, including VDPHL01, an oral, non-hormonal, extended-release minoxidil formulation designed for men and women. The company is also developing additional product candidates and delivery technologies for common skin and hair-related conditions such as alopecia areata, common warts, molluscum contagiosum, and atopic dermatitis. Veradermics serves healthcare providers, dermatology clinicians, and medical researchers involved in treating adult and pediatric patients. Headquartered in New Haven, Connecticut, and incorporated in 2019, Veradermics operates as a focused biotech company addressing prevalent dermatologic conditions through targeted therapeutic development.

MANE website: https://www.veradermics.com